{"organizations": [], "uuid": "54ef81d1941e607325682eebc3c9af89e7afe538", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/201510195758/genocea-biosciences-shares-dive-as-vaccine-candidate-misses-goals.aspx", "country": "US", "title": "Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T03:00:00.000+03:00", "replies_count": 0, "uuid": "54ef81d1941e607325682eebc3c9af89e7afe538"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/201510195758/genocea-biosciences-shares-dive-as-vaccine-candidate-misses-goals.aspx", "ord_in_thread": 0, "title": "Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Genocea Biosciences Inc. suspended development of its experimental pneumococcus vaccine after the treatment failed to show statistically significant results in a phase 2a study, missing primary study targets.\nShares of the Cambridge, Mass., drug developer fell 29% to $5.15 in recent premarket trading.\nGenocea said that pending further review of the data and potential paths forward, it plans to turn its focus to its immunotherapy treatment for genital herpes—known as GEN-003—which also is in phase 2 development.\nIn a study of 98 healthy adults Genocea's vaccine candidate—GEN-004—reduced the pneumococcal colonization rate by measured by microbiological culture, by between 22% and 25% versus a placebo and reduced the presence of pneumococcal DNA by between 18% and 36%.\nGenocea Chief Executive Chip Clark said in prepared remarks Monday that the company believes \"it is possible that future trials would require a change in some combination of dose, adjuvant or trial population to confirm any effect.\"\nPneumococcal disease is caused by Streptococcus pneumoniae bacteria and can lead to a range of illnesses including pneumonia, ear infections, sinus infections, meningitis and bloodstream infections, according to the Centers for Disease Control and Prevention website.\nWrite to Tess Stynes at tess.stynes@wsj.com\nSubscribe to WSJ: http://online.wsj.com?mod=djnwires\n 19, 2015 09:35 ET (13:35 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-10-19T03:00:00.000+03:00", "crawled": "2015-10-20T11:25:34.292+03:00", "highlightTitle": ""}